It sounds like you're considering switching from Humira to Cosentyx for treating your hidradenitis suppurativa (HS). Here's a comparison based on my knowledge base:
Cosentyx (Secukinumab)
- Type: Biologic disease-modifying antirheumatic drug (DMARD)
- Mechanism: Inhibits interleukin 17A (IL-17A), a chemical messenger Show Full Answer
It sounds like you're considering switching from Humira to Cosentyx for treating your hidradenitis suppurativa (HS). Here's a comparison based on my knowledge base:
Cosentyx (Secukinumab)
- Type: Biologic disease-modifying antirheumatic drug (DMARD)
- Mechanism: Inhibits interleukin 17A (IL-17A), a chemical messenger involved in HS inflammation.
- Administration: Subcutaneous injection every four weeks, or every two weeks if needed.
- Common Side Effects: Cold symptoms, upper respiratory tract infections, diarrhea.
- Serious Side Effects: Severe infections, inflammatory bowel disease, hypersensitivity reactions.
Humira (Adalimumab)
- Type: Biologic drug
- Mechanism: Neutralizes tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
- Administration: Subcutaneous injection every week or every other week after an initial loading dose.
- Common Side Effects: Respiratory infections, headache, redness or irritation at injection sites, rash.
- Serious Side Effects: Severe allergic reactions, potentially fatal infections, new or worsening heart failure, lupus-like syndrome, demyelinating disease, increased risk of certain cancers like lymphoma.
Considerations
- Effectiveness: Both drugs are FDA-approved for treating moderate to severe HS, but individual responses can vary.
- Side Effects: Consider the side effect profiles and discuss with your healthcare provider which might be more suitable for you.
- Administration Frequency: Cosentyx is typically administered less frequently than Humira, which might be more convenient.
It's important to consult with your healthcare provider to discuss your specific situation and determine the best treatment option for you.
September 23